GTC Biotherapeutics (fka GTCB)

[floblu14]

New Products & Partnering page on GTC Website -

I like, I like - Did DEW do - the graphics?

Notice FOB & ADCC -

Follow-On Biologics - CD20 Antibody
GTC and LFB Biotechnologies have initiated development of a transgenically produced CD20 monoclonal antibody under an existing agreement between the two companies. The resulting product is expected to have target specificity similar to Rituximab (Rituxan®, Mabthera®) and to have relatively higher antibody dependent cell-mediated cytotoxicity, or ADCC. The transgenically produced CD20 antibody is anticipated to be commercially developed for oncology and auto-immune indications. Rituximab is used in the treatment of B-cell non-Hodgkin's lymphoma, B-cell leukemia and rheumatoid arthritis. It is also under investigation for a range of auto-immune conditions such as systemic lupus erythematosus, immune thrombocytopenic purpura (ITP), and type-1 diabetes.

http://www.gtc-bio.com/products/prod.html